• Mirax Corporation appointed as exclusive distributor for Korea
• Important expansion of commercial opportunity in high-growth Asian IVD market
Melbourne, Australia, 22 January 2019: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer-related tests, continues its global expansion, signing a new distributor for South Korea.
The distribution agreement provides Mirax Corporation, Ltd. (Mirax) with the right to sell Sienna’s product to Korean pathology laboratories, where it will be used as an adjunct to urine cytology to assist pathologists and urologists in their diagnosis of bladder cancer.
For further information please download PDF attached:
Download this document
